ArticleBreast cancer (Dove Medical Press)2026
Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Purpose: Analyses of patients with early-stage, treatment-naïve triple-negative breast cancer (TNBC) have demonstrated that high glucocorticoid receptor (GR) expression in primary tumors is associated with poor prognosis. We previously observed that GR-high primary TNBCs exhibited significantly increased numbers of tumor-infiltrating regulatory T cells (Tregs) compared with GR-low tumors. To further investigate GR-associated immunologic features, we leveraged imaging mass cytometry (IMC) to profile additional immune cell phenotypes and spatial architecture in GR-high versus GR-low primary TNBC. Patients and Methods: Tumor-infiltrating immune cells were profiled in formalin-fixed paraffin-embedded (FFPE) core biopsies from five untreated GR-high and four GR-low TNBC tumors using IMC with a 21-antibody panel. Regions of interest (ROI) were selected within pan-cytokeratin-positive tumor nests. Data underwent unsupervised clustering, and cell types were identified based on protein expression profiles. Analyses compared cell-type abundance and spatial interactions in GR-high versus GR-low tumors. Results: GR-high tumors exhibited significantly greater Treg infiltration within tumor nests than GR-low tumors. GR-high TNBC also showed a comparatively greater abundance of activated memory CD8+ T cells, cytotoxic CD4+ T cells, and effector memory CD4+ T cells. In contrast, GR-low tumors exhibited relatively greater representation of HLA-ABC-positive (HLA-ABC+) cancer cells as well as early-activated dendritic cells (DCs) and natural killer (NK) cells. Spatial analysis revealed that Tregs in GR-high tumors colocalized more frequently with proliferating tumor cells relative to Tregs in GR-low tumors. NK cells in GR-high tumors displayed relatively less colocalization with proliferating tumor cells. Conclusion: Compared with GR-low disease, treatment-naïve GR-high primary TNBC exhibits a more immunosuppressive tumor microenvironment characterized by greater Treg density, closer Treg-cancer cell proximity, reduced NK cell infiltration, impaired immune surveillance, and decreased abundance of HLA-ABC+ cancer cells. These findings implicate TNBC cell GR signaling as immunosuppressive, likely through mechanisms resulting in both differential immune cell enrichment and altered spatial organization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.